SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. John M. de Castro who wrote (372)11/18/1998 10:13:00 PM
From: John Metcalf  Read Replies (1) of 4474
 
I don't know enough about GMED's core technology to comment on their comparability. The press release mentioned polymers, peptides, and lipids, which suggests more comparability to a lipid delivery system than a customizable dimer system. I didn't notice any reference to an apoptotic mechanism, which ARIA has. Like Ariad, GMED claims dose dependent expression levels, and the ability to turn protein expression on and off.

There are other posters to this thread who will be more able than I to compare the two approaches.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News